Cargando…
T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
Recent studies have highlighted a major role for cancer-associated fibroblasts (CAFs) in promoting immunotherapy resistance by excluding T cells from tumours. Recently, we showed that CAFs can be effectively targeted by inhibiting the enzyme NOX4; this ‘normalises’ CAFs and overcomes immunotherapy r...
Autores principales: | Hanley, Christopher J., Thomas, Gareth J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591574/ https://www.ncbi.nlm.nih.gov/pubmed/32830198 http://dx.doi.org/10.1038/s41416-020-1020-6 |
Ejemplares similares
-
Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy
por: Bodmer, Walter
Publicado: (2022) -
Precision intervention of cell type-specific targeting is required for future cancer immunotherapy
por: Cai, Yitong, et al.
Publicado: (2023) -
Proteasome inhibition—a new target for brain tumours
por: Rashid, Fatima, et al.
Publicado: (2019) -
CAF-immune cell crosstalk and its impact in immunotherapy
por: Maia, Ana, et al.
Publicado: (2022) -
Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives
por: Hanley, Christopher J., et al.
Publicado: (2021)